Retention in opioid agonist treatment during pregnancy and variations according to treatment and maternal characteristics
In New South Wales, Australia, from 2004 to 2021, over 84% of women receiving opioid agonist treatment during pregnancy were retained in treatment until childbirth; however, lower retention in later study years and among women initiating buprenorphine, coupled with recent guidelines recommending buprenorphine as first-line therapy during pregnancy, highlights the need for ongoing monitoring and targeted support to improve retention among women who are at higher risk of discontinuation.
Authors
- Chrianna Bharat (ORCID: https://orcid.org/0000-0002-9778-0386)
- Duong Thuy Tran (ORCID: https://orcid.org/0000-0002-1454-9462)
- Sallie‐Anne Pearson (ORCID: https://orcid.org/0000-0001-7137-6855)
- N. R. Jones (ORCID: https://orcid.org/0000-0002-5742-4598)
- Jonathan Brett (ORCID: https://orcid.org/0000-0003-3065-7495)
- Alys Havard
- Bianca Varney
- Ju‐Lee Oei
- Louisa Degenhardt
Institutions
- Royal Hospital for Women (AU)
- UNSW Sydney (AU)
- St Vincent's Hospital Sydney (AU)
- Women's & Children's Health Research Institute (AU)
- Mental Health Commission (AU)
- Sydney Local Health District (AU)
Publication Details
- Journal
- Addiction
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1111/add.70325
- Citations
- 1
- Primary Topic
- Prenatal Substance Exposure Effects
- Type
- article
- Field-Weighted Citation Impact
- 41.22